US Congress House Bill 2115 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Engrossed on October 29 2019 - 50% progression, died in committee
Action: 2019-10-29 - Received in the Senate and Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Engrossed) [PDF]

Requires the Centers for Medicare & Medicaid Services (CMS) to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs. Specifically, the CMS must publish certain information, as reported by PBMs, relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies, in accordance with specified confidentiality requirements. The bill also provides statutory authority for certain provisions of the CMS rule titled "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," published on May 23, 2019. The rule requires, in part, Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that is capable of integrating with at least one prescriber's electronic prescribing system or electronic health record. The tool must provide prescribers with patient-specific, real-time formulary and benefit information, including information regarding cost-sharing, formulary alternatives, and utilization management requirements. The rule takes effect January 1, 2021.

Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Rep. Abigail Spanberger [D-VA]	Rep. Jody Arrington [R-TX]	Rep. Brendan Boyle [D-PA]	Rep. Jeff Van Drew [R-NJ]
Rep. Elissa Slotkin [D-MI]	Rep. Nicholas Taylor [R-TX]

2019-10-28 - House - On motion to suspend the rules and pass the bill, as amended RC# 586 (Y: 403 N: 0 NV: 28 Abs: 0) [PASS]

Date	Chamber	Action
2019-10-29	Senate	Received in the Senate and Read twice and referred to the Committee on Finance.
2019-10-28	House	The title of the measure was amended. Agreed to without objection.
2019-10-28	House	Motion to reconsider laid on the table Agreed to without objection.
2019-10-28	House	On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586). (text: CR H8516)
2019-10-28	House	Considered as unfinished business. (consideration: CR H8520-8521)
2019-10-28	House	At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
2019-10-28	House	DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.
2019-10-28	House	Considered under suspension of the rules. (consideration: CR H8516-8519)
2019-10-28	House	Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.
2019-05-21	House	Subcommittee Hearings Held.
2019-04-09	House	Referred to the Subcommittee on Health.
2019-04-08	House	Referred to the Subcommittee on Health.
2019-04-08	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-04-08	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-04-08	House	Introduced in House

HB2113 (Related) 2020-12-24 - Placed on the Union Calendar, Calendar No. 571.
HB2296 (Related) 2019-09-24 - Placed on the Union Calendar, Calendar No. 170.
HB3408 (Related) 2019-06-24 - Referred to the Subcommittee on Health.
HB3415 (Related) 2019-06-24 - Referred to the Subcommittee on Health.
HB19 (Related) 2019-12-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
SB3129 (Related) 2019-12-19 - Read twice and referred to the Committee on Finance.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/house-bill/2115/all-info
Text	https://www.congress.gov/116/bills/hr2115/BILLS-116hr2115ih.pdf
Text	https://www.congress.gov/116/bills/hr2115/BILLS-116hr2115eh.pdf
Roll Call	https://clerk.house.gov/Votes/2019586